Skip to main content
. 2016 Aug 29;27(11):2090–2096. doi: 10.1093/annonc/mdw323

Figure 2.

Figure 2.

Kaplan–Meier curves of overall survival (A) and time to progression (B) in the sorafenib arm (blue line) and sorafenib plus hepatic arterial infusion chemotherapy with cisplatin arm (green line). The tick marks indicate censored cases.